Pharma Sees Promise in Cell-Based RNAi Screens, But Adjusts for a Few Limitations | GenomeWeb
This article has been updated from a previous version, which mistakenly reported that Klaus Melchers presented information on Altana's research instead of Michael Byrne.
SAN FRANCISCO – Pharmaceutical firms are finding cell-based RNAi screens to be a valuable drug-discovery tool, but are finding that the approach still has a number of limitations that need to be taken into account, according to speakers at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference, held here this week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.